Zila's OraTest
This article was originally published in The Gray Sheet
Executive Summary
Oral cancer detection system is slated for review by FDA's Oncologic Drugs Advisory Committee Jan. 13 at the Gaithersburg (Maryland) Holiday Inn. A new drug application for the diagnostic was accepted for filing Sept. 3 and assigned "priority review" status